To read the full story, subscribe or sign in.

Impact and Burning Rock team up to develop companion diagnostics for synthetic lethality drugs

Aug. 10, 2021

Burning Rock Biotech Ltd. has formed a global strategic partnership with Impact Therapeutics Inc. to develop companion diagnostics for a pipeline of drugs in the field of synthetic lethality.

BioWorld Asia Deals and M&A Drugs Cancer Diagnostics Asia-Pacific China

Today's news in brief

BioWorld

BioWorld briefs for April 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 7, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue

BioWorld

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune...